View in EDS

Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial.

Saved in:
Bibliographic Details
Title: Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial.
Authors: Thomas-Rüddel D; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Bauer M; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Moita LF; Instituto Gulbenkian de Ciência, Oeiras, Portugal., Helbig C; Center for Clinical Studies, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Schlattmann P; Institute of Medical Statistics, Computer Sciences, and Data Science, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Ehler J; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Rahmel T; Clinic for Anesthesiology, Intensive Care and Pain Therapy, University Medical Center Knappschaftskrankenhaus Bochum, Bochum, Germany., Meybohm P; Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, Germany., Gründling M; Department of Anesthesiology, Greifswald, University Hospital of Greifswald, Greifswald, Germany., Schenk H; Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany., Köcher T; Vienna BioCenter Core Facilities GmbH, Wien, Austria., Brunkhorst FM; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Gräler M; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Heger AJ; Center for Clinical Studies, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany., Weis S; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany sebastian.weis@med.uni-jena.de.; Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.; Leibniz Institute for Infection Biology and Natural Products Research, Hans-Knöll Institute - HKI, Jena, Germany.
Corporate Authors: EPOS-1 study group, SepNetCriticalCare TrialsGroup
Source: BMJ open [BMJ Open] 2024 Apr 22; Vol. 14 (4), pp. e075158. Date of Electronic Publication: 2024 Apr 22.
Publication Type: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
Journal Info: Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101552874 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-6055 (Electronic) Linking ISSN: 20446055 NLM ISO Abbreviation: BMJ Open Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 38653508
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Thomas-Rüddel+D%22">Thomas-Rüddel D</searchLink>; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.<br /><searchLink fieldCode="AU" term="%22Bauer+M%22">Bauer M</searchLink>; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.<br /><searchLink fieldCode="AU" term="%22Moita+LF%22">Moita LF</searchLink>; Instituto Gulbenkian de Ciência, Oeiras, Portugal.<br /><searchLink fieldCode="AU" term="%22Helbig+C%22">Helbig C</searchLink>; Center for Clinical Studies, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.<br /><searchLink fieldCode="AU" term="%22Schlattmann+P%22">Schlattmann P</searchLink>; Institute of Medical Statistics, Computer Sciences, and Data Science, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.<br /><searchLink fieldCode="AU" term="%22Ehler+J%22">Ehler J</searchLink>; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.<br /><searchLink fieldCode="AU" term="%22Rahmel+T%22">Rahmel T</searchLink>; Clinic for Anesthesiology, Intensive Care and Pain Therapy, University Medical Center Knappschaftskrankenhaus Bochum, Bochum, Germany.<br /><searchLink fieldCode="AU" term="%22Meybohm+P%22">Meybohm P</searchLink>; Department of Anaesthesiology, Intensive Care, Emergency and Pain Medicine, University Hospital Würzburg, Würzburg, Germany.<br /><searchLink fieldCode="AU" term="%22Gründling+M%22">Gründling M</searchLink>; Department of Anesthesiology, Greifswald, University Hospital of Greifswald, Greifswald, Germany.<br /><searchLink fieldCode="AU" term="%22Schenk+H%22">Schenk H</searchLink>; Department of Nephrology and Hypertension, Hannover Medical School, Hannover, Germany.<br /><searchLink fieldCode="AU" term="%22Köcher+T%22">Köcher T</searchLink>; Vienna BioCenter Core Facilities GmbH, Wien, Austria.<br /><searchLink fieldCode="AU" term="%22Brunkhorst+FM%22">Brunkhorst FM</searchLink>; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.<br /><searchLink fieldCode="AU" term="%22Gräler+M%22">Gräler M</searchLink>; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.<br /><searchLink fieldCode="AU" term="%22Heger+AJ%22">Heger AJ</searchLink>; Center for Clinical Studies, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.<br /><searchLink fieldCode="AU" term="%22Weis+S%22">Weis S</searchLink>; Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany sebastian.weis@med.uni-jena.de.; Institute for Infectious Disease and Infection Control, Jena University Hospital, Friedrich-Schiller-University, Jena, Germany.; Leibniz Institute for Infection Biology and Natural Products Research, Hans-Knöll Institute - HKI, Jena, Germany.
– Name: AuthorCorporate
  Label: Corporate Authors
  Group: Au
  Data: <searchLink fieldCode="CA" term="%22EPOS-1+study+group%22">EPOS-1 study group</searchLink><br /><searchLink fieldCode="CA" term="%22SepNetCriticalCare+TrialsGroup%22">SepNetCriticalCare TrialsGroup</searchLink>
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101552874%22">BMJ open</searchLink> [BMJ Open] 2024 Apr 22; Vol. 14 (4), pp. e075158. <i>Date of Electronic Publication: </i>2024 Apr 22.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial Protocol; Journal Article; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101552874 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-6055 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220446055%22">20446055 </searchLink><i>NLM ISO Abbreviation: </i>BMJ Open <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38653508
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1136/bmjopen-2023-075158
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e075158
    Titles:
      – TitleFull: Epirubicin for the Treatment of Sepsis and Septic Shock (EPOS-1): study protocol for a randomised, placebo-controlled phase IIa dose-escalation trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Thomas-Rüddel D
      – PersonEntity:
          Name:
            NameFull: Bauer M
      – PersonEntity:
          Name:
            NameFull: Moita LF
      – PersonEntity:
          Name:
            NameFull: Helbig C
      – PersonEntity:
          Name:
            NameFull: Schlattmann P
      – PersonEntity:
          Name:
            NameFull: Ehler J
      – PersonEntity:
          Name:
            NameFull: Rahmel T
      – PersonEntity:
          Name:
            NameFull: Meybohm P
      – PersonEntity:
          Name:
            NameFull: Gründling M
      – PersonEntity:
          Name:
            NameFull: Schenk H
      – PersonEntity:
          Name:
            NameFull: Köcher T
      – PersonEntity:
          Name:
            NameFull: Brunkhorst FM
      – PersonEntity:
          Name:
            NameFull: Gräler M
      – PersonEntity:
          Name:
            NameFull: Heger AJ
      – PersonEntity:
          Name:
            NameFull: Weis S
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 22
              M: 04
              Text: 2024 Apr 22
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-electronic
              Value: 2044-6055
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: BMJ open
              Type: main
ResultId 1